IL 233
Alternative Names: IL-233Latest Information Update: 28 Feb 2025
At a glance
- Originator Slate Bio
- Class Anti-inflammatories; Cytokines; Interleukins
- Mechanism of Action Interleukin replacements; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Feb 2025 No recent reports of development identified for preclinical development in Inflammation in USA
- 21 Jan 2021 Preclinical trials in Autoimmune disorders in USA (unspecified route)